Caris Life Sciences cash flow, quarter by quarter

In Q3 2026, Caris Life Sciences generated −$22.2M of operating cash flow and spent $17.5M on capital projects, leaving free cash flow of −$39.7M. That is $95.0M less than in Q3 2025 ($55.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was $83.9M; the largest uses were net borrowing (+) / repaid (−) ($406M), other investing ($155M), buybacks ($31.5M); besides operations, cash came from other financing ($395M), shares issued ($29.9M); the cash balance fell by $89.8M.

Operating cash flow was −$22.2M against net income of $15.2M — -1.5× profit, less cash than reported earnings, worth checking against working capital. The largest differences: payables −$21.6M, stock-based pay +$18.5M, receivables −$16.4M.

Caris Life Sciences funds itself: free cash flow was $83.9M over the last twelve months, and $922M of cash and investments stands against $393M of debt ($89K due within a year, 10359.1× covered by cash).